Breast Cancer Screening and Early Detection (ECCO2017 Society Day)

Chairs: F. Cardoso, PT - C. de Wolf, CH - J. Geraghty, IE


INTRODUCTION
Tomosynthesis carries a great promise in improving cancer detection and reducing the number of false positives. As yet its drawbacks are: higher and longer radiation exposure, longer compression time and therefore longer lasting pain and longer interpretation time. However, is there a role for tomosynthesis in screening?

This conference topic will address many elements. Is tomosynthesis the better screening mammogram? Does digital breast tomosynthesis (DBT) reduce interval cancers? What are the technical hurdles (compatibility, data volumes) to use DBT in screening? How to compare with previous mammograms? Is DBT screening cost effective? What are the views of screening programs and the European Commission?  
Is there a future for “Risk based screening”? There is a variable breast cancer risk in the population. You can think of familial risk factors, genetic risk factors, breast density but also age. Often some of these subgroups are excluded from screening or need additional imaging. Is it possible for a screening program to offer personalized services for high risk groups and how can we calculate the risk level?


MAIN TOPICS
• Breast Cancer screening programs and policies
• Is Tomosynthesis Ready for Prime Time?
• Risk based screening
• Hot topics in breast screening



Registration to the ESO Society Day can be done via the ECCO website.





FURTHER INFORMATION
Alexandra Zampetti, azampetti@eso.net, +41.91.820.09.54

FACULTY

Chairs
F. Cardoso, Champalimaud Clinical Centre, Lisbon, PT
C. de Wolf, ADSAN Sarl, Onex, CH
J. Geraghty, University College Dublin, IE

Faculty
B. Borisch, University of Geneva, Geneva, CH
M. Broeders, Radboud University Medical Center, Nijmegen, NL
A. De Censi, E. O. Ospedali Galliera, Genova, IT
N. de Jong, RIVM Centrum voor Bevoklingsonderzoek, Bilthoven, NL
H. de Koning, Erasmus University, Rotterdam, NL
S. Duffy, Queen Mary University of London, UK
S. Heywang, Referenzzentrum Mammographie München, Munich, DE
S. Hofvind, Cancer Registry of Norway, Oslo, NO
C. Normand, Trinity College Dublin, Dublin, IE
F. Peccatori, European School of Oncology and Istituto Europeo di Oncologia, Milano, IT
M. Solbjor, Norwegian University of Science and Technology, Trondheim, NO
E. van Veen, Med Law consult, Den Haag, NL
S. Zackrisson, Skane University Hospital Malmö, Malmö, SE

PROGRAMME
27 JANUARY 2017

BREAST SCREENING PROGRAMMES & POLICIES Chair: F. Cardoso, PT
9:00		Introductory remarks C. De Wolf, CH
9:10		Understanding Differences in Screening Effect from Observational Studies S. Duffy, UK
9:30		Health Economics in Screening C. Normand, IE
9:50		Informed Decision–making for Women - Is it possible? M. Solbjor, NO
10:10		Discussion
10:30		Coffee
IS TOMOSYNTHESIS READY FOR PRIME TIME? Chair: C.s de Wolf, CH
11:00		Adding Tomosynthesis to Mammography for Population Screening   S. Hofvind, NO
11:20		Tomosynthesis-only Compared to Conventional Screening S. Heywang, DE
11:40		Decision models on tomosysnthesis in the Netherlands N. de Jong, NL
12:00		Medical, Legal and Ethical implications of Tomosynthesis in Screening E.B. van Veen, NL
12:20		Discussion
12:40		Lunch
RISK-BASED SCREENING Chair:  J. Geraghty, IE
14:00		Eu-topia TOwards imProved screening In All of EUrope H. de Koning, NL
14:20		Conceptual issues regarding risk based screening M. Broeders, NL
14:40		Chemoprevention or Screening? A. De Censi, IT
15:00		Discussion
15:30		Coffee
HOT TOPICS IN BREAST SCREENING Chair: F.A. Peccatori, IT
16:00		Should breast screening be mandatory? B. Borish, CH
16:20		Breast Screening in Europe and New European Breast Guidelines C. de Wolf, CH
16:40		Breast Screening in 2025: a challenging forecast (neural network diagnosis) S. Zackrisson, SE
17:00		Discussion
17:20		Closing remarks